C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Ruben A. Mesa,Nicolaas Schaap,Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Francesco Passamonti,Sonja Zweegman,Moshe Talpaz,Srdan Verstovsek,Shelonitda Rose,Pranav Abraham,Jennifer Lord-Bessen,Derek Tang,Shien Guo,Xiaomei Ye,Claire N. Harrison +14 more
TL;DR: Fedratinib, an oral, selective Januskinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, phase III JAKARTA study in adult patients with intermediate- or high-risk JAK-inhibitor-naive MF.
Journal ArticleDOI
Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
Jean-Jacques Kiladjian,Srdan Verstovsek,Martin Griesshammer,Tamás Masszi,Simon Durrant,Francesco Passamonti,Claire N. Harrison,Fabrizio Pane,Pierre Zachee,Keita Kirito,Carlos Besses,Masayuki Hino,Ana Ines Varela,Carole B. Miller,Elisa Rumi,Vittorio Rosti,Igor Wolfgang Blau,Ruben A. Mesa,Tuochuan Dong,Nathalie Francillard,Mary J. Laughlin,Alessandro M. Vannucchi +21 more
TL;DR: The 80-wk follow-up data confirmed that the probability of maintaining primary and hematocrit responses with rux treatment was 92% and 89%, respectively, and hence, rux could be an effective long-term therapy option for hydroxyurea (HU)-resistant/intolerant (R/I) pts with PV.
Journal ArticleDOI
A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
Florian H. Heidel,Vincent Ribrag,Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Francesco Passamonti,Amjad Hayat,Eibhlin Conneally,Thomas Kindler,Bruno Martino,Daniel B. Lipka,Suddhasatta Acharyya,Florence Binlich,Tracy Liu,Song Mu,Claire N. Harrison +14 more
TL;DR: The updated results of a phase 1b study of the combination of RUX and PAN in MF patients with palpable splenomegaly show synergistic anti-MF activity in preclinical studies.
Journal ArticleDOI
Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)
Jean-Jacques Kiladjian,Pierre Zachee,Masayuki Hino,Fabrizio Pane,Tamás Masszi,Claire N. Harrison,Ruben A. Mesa,Carole B. Miller,Francesco Passamonti,Simon Durrant,Martin Griesshammer,Keita Kirito,Carles Besses,Beatriz Moiraghi,Elisa Rumi,Vittorio Rosti,Igor Wolfgang Blau,Nathalie Francillard,Tuochuan Dong,Monika Wroclawska,Alessandro M. Vannucchi,Srdan Verstovsek +21 more
TL;DR: The 4-year follow-up confirmed that primary and clinicohematologic (CLHM) responses were sustained with the rux treatment, and the safety profile was consistent with previous reports, and long-term efficacy and safety was reported.
Journal ArticleDOI
High Prevalence of Mood Disorders in MPNs and Their Possible Role in MPN Related Fatigue
Robyn M. Scherber,Zhenya Senyak,Amylou C. Dueck,Matthew M. Clark,Michael Boxer,Archie McCallister,Mary Cotter,Barbara VanHusen,Claire N. Harrison,Ruben A. Mesa +9 more
TL;DR: A 70-item internet-based survey was developed by MPN investigators and patient/advocates and hosted by the Mayo Clinic Survey Research Center and found many significant correlations were observed between MPN-SAF items and PHQ, MHI-5, and POMS-B.